Lealtx
Worcester, US · 2 known investors
Leal Therapeutics develops first-in-class neuro-metabolic therapeutics for central nervous system disorders, including oral small molecules and antisense oligonucleotides targeting metabolic pathways underlying neuropsychiatric and neurodegenerative diseases such as schizophrenia, ALS, and Alzheimer's. Its pipeline includes GLS1 and SPT inhibitors and a delivery platform designed to transport therapeutics across the blood-brain barrier.
Investors · 2
Frequently asked questions
- What does Lealtx do?
- Leal Therapeutics develops first-in-class neuro-metabolic therapeutics for central nervous system disorders, including oral small molecules and antisense oligonucleotides targeting metabolic pathways underlying neuropsychiatric and neurodegenerative diseases such as schizophrenia, ALS, and Alzheimer's. Its pipeline includes GLS1 and SPT inhibitors and a delivery platform designed to transport therapeutics across the blood-brain barrier.
- Who are Lealtx's investors?
- Lealtx's investors include OrbiMed, Newpath Partners.
- Where is Lealtx headquartered?
- Lealtx is headquartered in Worcester, US.